The prostate: Decreasing cost-effectiveness of biopsy with advancing age

Investigative Radiology

Volumn 31, Issue 2, 1996, Pages 84-90

  Gottlieb, Ronald H ^a   Mooney, Cathleen ^a   Mushlin, Alvin I ^a   Rubens, Deborah J ^a   Fultz, Patrick J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

biopsy; Prostate specific antigen; ultrasound

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; ULTRASOUND;

EID: 0030038020     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199602000-00005     Document Type: Article

References (21)

1. Garfinkel L. Evaluating cancer statistics. CA Cancer J Clin 1994;44:5-6. Editorial.
2. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
3. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: A decision analytic view. JAMA 1994;272:773-780.
4. Lee F, Littrup PJ, Loft-Christensen L, et al. Predicted prostate-specific antigen results using transrectal ultrasound gland volume: Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 1992;70(suppl 1):211-220.
5. Maldonado CJ, Rubens DJ, Gottlieb RH. Patient management using excess PSA improves biopsy yield for prostate carcinoma. Presented at the Association of University Radiologists meeting, May 1994, Boston, MA.
6. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr., eds. Campbell's urology. Philadelphia, PA: WB Saunders Co., 1992:1159-1221.
7. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(suppl 3):933-938.
8. Pollack A, Zagars GK, Kavadi vs. Prostate-specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994;74:670-678.
9. Pollack A, Zagars GK, el-Naggar AK, Terry NH. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 1994;44: 711-718.
10. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin 1993;43:134-149.
11. Narayan P. Neoplasms of the prostate gland. In: Tanagho EA, McAninch JW, eds. Smith's general urology. Norwalk, CT: Appleton & Lange, 1992:378-412.
12. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-2196.
13. Sox HC, Blatt MA, Higgins MC, Marton KI. Measuring the outcome of care. Med Decis Making 1988:167-200.
14. Chow P, Wong M, Foo KT. Clinical profile of stage D carcinoma of the prostate: A 10-year experience. Ann Acad Med Singapore 1993;22:254-256.
15. Barry MJ, Mulley AG Jr., Fowler FJ, Wennberg JW. Watchful waiting vs immediate transurethral resection for symptomatic prostatism: The importance of patients' preferences. JAMA 1988;259:3010-3017.
16. Krumins PE, Fihn SD, Kent DL. Symptom severity and patients' values in the decision to perform a transurethral resection of the prostate. Med Decis Making 1988;8:1-8.
17. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-1167.
18. Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994;74:1615-1620.
19. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993;150:1837-1839.
20. Oesterling JE, Cooner WH, Jacobsen SJ, et al. Influence of patient age on the serum PSA concentration: An important clincal observation. Urol Clin North Am 1993;20:671-680.
21. Ross JS, Figge H, Bui HX, et al: Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994;74:2811-2818.